E. Gane

405 total citations
30 papers, 256 citations indexed

About

E. Gane is a scholar working on Hepatology, Epidemiology and Infectious Diseases. According to data from OpenAlex, E. Gane has authored 30 papers receiving a total of 256 indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Hepatology, 19 papers in Epidemiology and 8 papers in Infectious Diseases. Recurrent topics in E. Gane's work include Hepatitis C virus research (24 papers), Hepatitis B Virus Studies (14 papers) and Liver Disease Diagnosis and Treatment (12 papers). E. Gane is often cited by papers focused on Hepatitis C virus research (24 papers), Hepatitis B Virus Studies (14 papers) and Liver Disease Diagnosis and Treatment (12 papers). E. Gane collaborates with scholars based in United States, New Zealand and Canada. E. Gane's co-authors include Satawat Thongsawat, Jenny Heathcote, Ching‐Lung Lai, John G. McHutchison, Sarah Arterburn, Nathaniel Brown, Patrick Marcellin, Marı́a Buti, William T. Symonds and Nezam H. Afdhal and has published in prestigious journals such as Journal of Hepatology, Annals of Oncology and Clinical Gastroenterology and Hepatology.

In The Last Decade

E. Gane

28 papers receiving 248 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
E. Gane United States	9	237	227	43	16	9	30	256
Giampaolo Mangia Italy	7	239 1.0×	256 1.1×	31 0.7×	11 0.7×	8 0.9×	7	281
H.W. Reesink Netherlands	9	175 0.7×	178 0.8×	49 1.1×	19 1.2×	37 4.1×	24	219
Ahmed F. Sherief Egypt	7	165 0.7×	167 0.7×	54 1.3×	11 0.7×	8 0.9×	20	246
Mark Sulkowski United States	4	257 1.1×	268 1.2×	20 0.5×	20 1.3×	3 0.3×	6	310
Junfeng Lu China	10	275 1.2×	300 1.3×	30 0.7×	27 1.7×	45 5.0×	32	359
Qin-Yan Chen China	8	216 0.9×	248 1.1×	23 0.5×	21 1.3×	11 1.2×	18	273
Cecilia Marrocco Italy	11	466 2.0×	454 2.0×	65 1.5×	9 0.6×	11 1.2×	15	500
Zu‐Jiang Yu China	9	104 0.4×	111 0.5×	30 0.7×	27 1.7×	21 2.3×	15	184
A.R. Türkyilmaz Türkiye	9	359 1.5×	368 1.6×	67 1.6×	14 0.9×	11 1.2×	15	394
Sophie B. Willemse Netherlands	12	205 0.9×	210 0.9×	29 0.7×	45 2.8×	19 2.1×	21	283

Countries citing papers authored by E. Gane

Since Specialization

Citations

This map shows the geographic impact of E. Gane's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by E. Gane with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites E. Gane more than expected).

Fields of papers citing papers by E. Gane

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by E. Gane. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by E. Gane. The network helps show where E. Gane may publish in the future.

Co-authorship network of co-authors of E. Gane

This figure shows the co-authorship network connecting the top 25 collaborators of E. Gane. A scholar is included among the top collaborators of E. Gane based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with E. Gane. E. Gane is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Decaens, Thomas, T. Yau, Jung‐Won Park, et al.. (2024). 965MO Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line (1L) treatment for unresectable hepatocellular carcinoma (uHCC): Expanded analyses from CheckMate 9DW. Annals of Oncology. 35. S657–S657. 5 indexed citations

Gane, E., Florin Alexandru Căruntu, Vithika Suri, et al.. (2018). Safety and efficacy at 1 year after switching from Tenofovir Disoproxil Fumurate to Tenofovir Alafenamide in chronic HBV patients with risk factors for TDF use. Journal of Hepatology. 68. S87–S87. 6 indexed citations

Gane, E., Christian Schwabe, Lin Gao, et al.. (2018). RO7020531, a novel prodrug of a toll-like receptor 7 agonist, is safe, well tolerated and activates TLR signaling in healthy volunteers. Journal of Hepatology. 68. S514–S515. 5 indexed citations

Gane, E., F. Poordad, Joaquin Valdes, et al.. (2017). Pharmacokinetics and safety of glecaprevir/pibrentasvir in adults with chronic genotype 1–6 hepatitis C virus infection and compensated cirrhosis: an integrated analysis. Journal of Hepatology. 66(1). S306–S306. 3 indexed citations

Shafran, Stephen D., Douglas W. Shaw, Kosh Agarwal, et al.. (2017). Efficacy and safety results of patients with HCV genotype 2 or 3 infection treated with ombitasvir/paritaprevir/ritonavir and sofosbuvir with or without ribavirin (QUARTZ II‐III). Journal of Viral Hepatitis. 25(2). 118–125. 9 indexed citations

Younossi, Zobair M., Maria Stepanova, Ira M. Jacobson, et al.. (2017). High efficacy is accompanied with substantial gains in patient reported outcomes in cirrhotic patients with chronic hepatitis C treated with sofosbuvir (SOF), velpatasvir with or without voxilaprevir (VOX): data from POLARIS 1, 2, 3 and 4. Journal of Hepatology. 66(1). S114–S114. 1 indexed citations

Kwo, Paul Y., F. Poordad, Ariel Porcalla, et al.. (2016). Safety of ABT-493 and ABT-530 Co-Administered in Patients with HCV Genotype 1–6 Infection: Results from the Surveyor-I and Surveyor-II Studies. Journal of Hepatology. 64(2). S809–S809. 4 indexed citations

Chuang, Wan‐Long, Henry Lik‐Yuen Chan, Tawesak Tanwandee, et al.. (2016). HBeAg Seroconversion Rates after Five Years of Follow-Up in Patients Treated with Peginterferon Alfa-2a (40kd) in Neptune: Final Results of the Son of Neptune Long-Term Follow-Up Study. Journal of Hepatology. 64(2). S604–S604. 1 indexed citations

Dore, G.J., Frederick L. Altice, Alain H. Litwin, et al.. (2016). C-Edge Co-Star: Risk of Reinfection following Successful Therapy with Elbasvir and Grazoprevir in Persons who Inject Drugs (PWID) Receiving Opioid Agonist Therapy (OAT). Journal of Hepatology. 64(2). S771–S771. 8 indexed citations

10.

Shafran, Stephen, David Shaw, Kosh Agarwal, et al.. (2016). QUARTZ II-III: Final Efficacy and Safety Results in Patients with HCV Genotype 2 or 3 Infection Treated With Ombitasvir/Paritaprevir/Ritonavir and Sofosbuvir With or Without Ribavirin. Queen Mary Research Online (Queen Mary University of London). 1 indexed citations

11.

Gane, E., et al.. (2015). Hepatocellular Carcinoma Occurence in Non-alcoholic Fatty Liver Disease Without Established Cirrhosis. Clinical Gastroenterology and Hepatology. 13(7). e118–e119. 1 indexed citations

12.

Ferenci, Péter, Xavier Forns, Eric Lawitz, et al.. (2014). Simeprevir (TMC435) with Peginterferon/Ribavirin for treatment of chronic HCV genotype 1 infection in european patients who relapsed after previous interferon-based therapy: the promise trial. Zeitschrift für Gastroenterologie. 52(5). 61.

13.

Afdhal, Nezam H., Greg Everson, José Luís Calleja, et al.. (2014). O68 SOFOSBUVIR AND RIBAVIRIN FOR THE TREATMENT OF CHRONIC HCV WITH CIRRHOSIS AND PORTAL HYPERTENSION WITH AND WITHOUT DECOMPENSATION: EARLY VIROLOGIC RESPONSE AND SAFETY. Journal of Hepatology. 60(1). S28–S28. 45 indexed citations

14.

Gane, E., Zhiqiang Yan, Teerha Piratvisuth, et al.. (2012). 509 TELBIVUDINE (LDT) TREATMENT EFFECT ON GLOMERULAR FILTRATION RATE (GFR) IN CHRONIC HEPATITIS B (CHB) PATIENTS WITH POTENTIAL RISKS OF RENAL DYSFUNCTION. Journal of Hepatology. 56. S200–S201. 1 indexed citations

15.

Fung, Scott, Marı́a Buti, E. Gane, et al.. (2012). 508 IS HBEAG LOSS ASSOCIATED WITH AN IMPROVED OUTCOME IN HEPATITIS B PATIENTS TREATED WITH TENOFOVIR DISOPROXIL FUMARATE (TDF)?. Journal of Hepatology. 56. S200–S200. 4 indexed citations

16.

Gane, E., E.J. Heathcote, Patrick Marcellin, et al.. (2010). 1006 HBSAG KINETICS OF DECAY AND BASELINE CHARACTERISTICS OF HBEAG-POSITIVE PATIENTS WITH CHRONIC HEPATITIS B FOLLOWING 3 YEARS OF TENOFOVIR DISOPROXIL FUMARATE (TDF) TREATMENT. Journal of Hepatology. 52. S388–S388. 12 indexed citations

17.

Gane, E., Graham R. Foster, J Cianciara, et al.. (2010). 2003 ANTIVIRAL ACTIVITY, PHARMACOKINETICS, AND TOLERABILITY OF AZD7295, A NOVEL NS5A INHIBITOR, IN A PLACEBO-CONTROLLED MULTIPLE ASCENDING DOSE STUDY IN HCV GENOTYPE 1 AND 3 PATIENTS. Journal of Hepatology. 52. S464–S464. 14 indexed citations

18.

Rasenack, J., Thierry Poynard, Ching‐Lung Lai, et al.. (2007). [513] EFFICACY OF TELBIVUDINE VS LAMIVUDINE AT 2 YEARS IN PATIENTS WITH HBeAg-POSITIVE CHRONIC HEPATITIS B WHO ARE ELIGIBLE FOR TREATMENT BASED ON GUIDELINES. Journal of Hepatology. 46. S195–S195. 5 indexed citations

19.

Piratvisuth, Teerha, Patrick Marcellin, Satawat Thongsawat, et al.. (2006). 50 Durability of response and occurrence of late response to peginterferon alpha-2a (40KD) [PEGASYS] one year post-treatment in patients with HBeAg-positive chronic hepatitis B. Journal of Hepatology. 44. S23–S24. 29 indexed citations

20.

Lai, Ching‐Lung, E. Gane, Y‐F Liaw, et al.. (2005). Telbivudine (LdT) vs. lmivudine for chronic Hepatitis B: First-year results from the international phase III GLOBE trial. 30 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact